Biotech Values

[poorgradstudent]

>Morbidity and mortality are the proper endpoints.<

hahah ok... the circle is complete!

So we're back to the point that you basically want a phase III trial instead of a phase II, or you want an underpowered trial to measure mortality / morbidity to determine if you should measure mortality / morbidity in an appropriately powered trial.

I think it is a safe bet that they have the morbidity / mortality data from the phase II trial that they ran. They simply didn't publish it for us to see.

Anyways, colour me confused yet ambivalent at this point.